mRNA vaccines: a Latin American perspective

According to UNICEF's State of the World's Children 2023 report, in Latin America and the Caribbean, 6.8 million children did not benefit from vaccination during the time of the pandemic and in the following two years, progress has not been as expected either.

For this reason, one of the great challenges is to raise vaccination rates to the levels they had before COVID-19, writes The Pharma Letter's local correspondent.

To achieve this goal, work is being done  through actions such as 'Vaccination Week in the Americas 2024', led by the Pan American Health Organization (PAHO); calls to action such as 'Act now to protect your future. #Vacúnate'; and campaigns such as 'Compas en Vax' by the Latin American Association of the Pharmaceutical Industry (Fifarma), an invitation to see vaccination as a social activity, where couples, family, friends and neighbors support each other to create a healthier and more resilient community.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology